HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Plasma amyloid-β ratios in autosomal dominant Alzheimer's disease: the influence of genotype.

Abstract
In vitro studies of autosomal dominant Alzheimer's disease implicate longer amyloidpeptides in disease pathogenesis; however, less is known about the behaviour of these mutations in vivo. In this cross-sectional cohort study, we used liquid chromatography-tandem mass spectrometry to analyse 66 plasma samples from individuals who were at risk of inheriting a mutation or were symptomatic. We tested for differences in amyloid-β (Aβ)42:38, Aβ42:40 and Aβ38:40 ratios between presenilin 1 (PSEN1) and amyloid precursor protein (APP) carriers. We examined the relationship between plasma and in vitro models of amyloid-β processing and tested for associations with parental age at onset. Thirty-nine participants were mutation carriers (28 PSEN1 and 11 APP). Age- and sex-adjusted models showed marked differences in plasma amyloid-β between genotypes: higher Aβ42:38 in PSEN1 versus APP (P < 0.001) and non-carriers (P < 0.001); higher Aβ38:40 in APP versus PSEN1 (P < 0.001) and non-carriers (P < 0.001); while Aβ42:40 was higher in both mutation groups compared to non-carriers (both P < 0.001). Amyloid-β profiles were reasonably consistent in plasma and cell lines. Within the PSEN1 group, models demonstrated associations between Aβ42:38, Aβ42:40 and Aβ38:40 ratios and parental age at onset. In vivo differences in amyloid-β processing between PSEN1 and APP carriers provide insights into disease pathophysiology, which can inform therapy development.
AuthorsAntoinette O'Connor, Josef Pannee, Teresa Poole, Charles Arber, Erik Portelius, Imogen J Swift, Amanda J Heslegrave, Emily Abel, Nanet Willumsen, Helen Rice, Philip S J Weston, Natalie S Ryan, James M Polke, Jennifer M Nicholas, Simon Mead, Selina Wray, Lucía Chávez-Gutiérrez, Chris Frost, Kaj Blennow, Henrik Zetterberg, Nick C Fox
JournalBrain : a journal of neurology (Brain) Vol. 144 Issue 10 Pg. 2964-2970 (11 29 2021) ISSN: 1460-2156 [Electronic] England
PMID33892504 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.
Chemical References
  • Amyloid beta-Peptides
  • Biomarkers
  • PSEN1 protein, human
  • Presenilin-1
Topics
  • Adult
  • Alzheimer Disease (blood, diagnosis, genetics)
  • Amyloid beta-Peptides (blood, genetics)
  • Biomarkers (blood)
  • Cohort Studies
  • Cross-Sectional Studies
  • Female
  • Genotype
  • Humans
  • Induced Pluripotent Stem Cells (metabolism)
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Presenilin-1 (blood, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: